Dalfampridine Holds Potential for MS-Related Balance Impairment

Key clinical point: Dalfampridine may be a treatment option for balance impairment associated with multiple sclerosis (MS).

Major finding: The dalfampridine treated group demonstrated better balance in both single- (quiet standing test) and dual-task (Stroop test) conditions than the placebo group; however, the benefits of dalfampridine were not retained beyond 4 weeks after discontinuation of treatment.

Study details: A substudy of a randomized, double-blind, placebo-controlled trial in which patients received dalfampridine 10 mg (27 patients) or placebo (14 patients) twice a day for 12 weeks.

Disclosures: The original trial was funded by Biogen. The corresponding author disclosed consultancy with Almirall, Biogen, Novartis, Genzyme, Roche, and Teva and research funding from Associazione Italiana Sclerosi Multipla and Genzyme.

Citation: Prosperini L, et al. Neurotherapeutics. 2019 Dec 9. doi: 10.1007/s13311-019-00813-5.

Key clinical point: Dalfampridine may be a treatment option for balance impairment associated with multiple sclerosis (MS).

Major finding: The dalfampridine treated group demonstrated better balance in both single- (quiet standing test) and dual-task (Stroop test) conditions than the placebo group; however, the benefits of dalfampridine were not retained beyond 4 weeks after discontinuation of treatment.

Study details: A substudy of a randomized, double-blind, placebo-controlled trial in which patients received dalfampridine 10 mg (27 patients) or placebo (14 patients) twice a day for 12 weeks.

Disclosures: The original trial was funded by Biogen. The corresponding author disclosed consultancy with Almirall, Biogen, Novartis, Genzyme, Roche, and Teva and research funding from Associazione Italiana Sclerosi Multipla and Genzyme.

Citation: Prosperini L, et al. Neurotherapeutics. 2019 Dec 9. doi: 10.1007/s13311-019-00813-5.

Key clinical point: Dalfampridine may be a treatment option for balance impairment associated with multiple sclerosis (MS).

Major finding: The dalfampridine treated group demonstrated better balance in both single- (quiet standing test) and dual-task (Stroop test) conditions than the placebo group; however, the benefits of dalfampridine were not retained beyond 4 weeks after discontinuation of treatment.

Study details: A substudy of a randomized, double-blind, placebo-controlled trial in which patients received dalfampridine 10 mg (27 patients) or placebo (14 patients) twice a day for 12 weeks.

Disclosures: The original trial was funded by Biogen. The corresponding author disclosed consultancy with Almirall, Biogen, Novartis, Genzyme, Roche, and Teva and research funding from Associazione Italiana Sclerosi Multipla and Genzyme.

Citation: Prosperini L, et al. Neurotherapeutics. 2019 Dec 9. doi: 10.1007/s13311-019-00813-5.